BRPI0210076B8 - preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato - Google Patents

preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato

Info

Publication number
BRPI0210076B8
BRPI0210076B8 BRPI0210076A BRPI0210076B8 BR PI0210076 B8 BRPI0210076 B8 BR PI0210076B8 BR PI0210076 A BRPI0210076 A BR PI0210076A BR PI0210076 B8 BRPI0210076 B8 BR PI0210076B8
Authority
BR
Brazil
Prior art keywords
preparation
tocopherol
alpha
influenza virus
influenza
Prior art date
Application number
Other languages
English (en)
Inventor
Eichhorn Uwe
Original Assignee
Glaxosmithkline Biologicals Branch Of Smithkline Beecham Pharma Gmbh & Co Kg
Saechsisches Serumwerk Dresden Branch Of Smithkline Beecham Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0113083A external-priority patent/GB0113083D0/en
Priority claimed from GB0204116A external-priority patent/GB0204116D0/en
Application filed by Glaxosmithkline Biologicals Branch Of Smithkline Beecham Pharma Gmbh & Co Kg, Saechsisches Serumwerk Dresden Branch Of Smithkline Beecham Pharma Gmbh filed Critical Glaxosmithkline Biologicals Branch Of Smithkline Beecham Pharma Gmbh & Co Kg
Publication of BR0210076A publication Critical patent/BR0210076A/pt
Publication of BRPI0210076A8 publication Critical patent/BRPI0210076A8/pt
Publication of BRPI0210076B1 publication Critical patent/BRPI0210076B1/pt
Publication of BRPI0210076B8 publication Critical patent/BRPI0210076B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

preparação de vírus da influenza inativado,vacina de influenza, métodos para a preparação de um antígeno de hemaglutinina estável e para a profilaxia da 5 doença ou infecção de influenza em um indivíduo, e, uso de alfa-tocoferol ou succinato uma preparação de vírus da influenza inativado é descrita a qual compreende um antígeno de hemaglutinina estabilizado na ausência de tiomersal, ou em níveis baixos de tiomersal, na qual a hemaglutinina é detectável por um ensaio de srd. a preparação de vírus da influenza pode compreender um excipiente modificador de micela, por exemplo (alfa)-tocoferol ou um seu derivado em uma quantidade suficiente para estabilizar a hemaglutinina.
BR0210076-2 2001-05-30 2002-05-29 preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato BRPI0210076B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0113083.0 2001-05-30
GB0113083A GB0113083D0 (en) 2001-05-30 2001-05-30 Novel compounds
GB0204116.8 2002-02-21
GB0204116A GB0204116D0 (en) 2002-02-21 2002-02-21 Novel vaccine composition
PCT/EP2002/005883 WO2002097072A2 (en) 2001-05-30 2002-05-29 Influenza vaccine composition

Publications (4)

Publication Number Publication Date
BR0210076A BR0210076A (pt) 2004-06-22
BRPI0210076A8 BRPI0210076A8 (pt) 2017-05-23
BRPI0210076B1 BRPI0210076B1 (pt) 2020-01-07
BRPI0210076B8 true BRPI0210076B8 (pt) 2021-05-25

Family

ID=30445235

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210076-2 BRPI0210076B8 (pt) 2001-05-30 2002-05-29 preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato

Country Status (30)

Country Link
US (2) US7316813B2 (pt)
EP (3) EP1407008B1 (pt)
JP (1) JP4074582B2 (pt)
KR (1) KR100871021B1 (pt)
CN (2) CN101069744B (pt)
AR (1) AR036039A1 (pt)
AT (1) ATE420159T1 (pt)
AU (2) AU2002344182C1 (pt)
BR (1) BRPI0210076B8 (pt)
CA (1) CA2448208C (pt)
CO (1) CO5540349A2 (pt)
CY (1) CY1108930T1 (pt)
CZ (1) CZ298697B6 (pt)
DE (1) DE60230760D1 (pt)
DK (1) DK1407008T3 (pt)
ES (1) ES2318020T3 (pt)
FR (1) FR13C0072I1 (pt)
HK (1) HK1067891A1 (pt)
HU (1) HU229368B1 (pt)
IL (2) IL158931A (pt)
MX (1) MXPA03010944A (pt)
MY (1) MY134424A (pt)
NO (1) NO335212B1 (pt)
NZ (1) NZ529755A (pt)
PL (1) PL206435B1 (pt)
PT (1) PT1407008E (pt)
SI (1) SI1407008T1 (pt)
TW (1) TWI228420B (pt)
WO (1) WO2002097072A2 (pt)
ZA (1) ZA200309250B (pt)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE376825T1 (de) * 1999-09-24 2007-11-15 Glaxosmithkline Biolog Sa Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
US7262045B2 (en) 2003-02-25 2007-08-28 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
DE602005024827D1 (de) 2004-09-09 2010-12-30 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
EP1796719B1 (en) * 2004-10-06 2014-12-03 MedImmune, LLC Refrigerator-temperature stable influenza vaccine compositions
WO2006062637A2 (en) * 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics Inc. Influenza vaccination
US9161905B2 (en) * 2005-01-12 2015-10-20 Ocular Research Of Boston, Inc. Dry eye treatment
WO2006100109A1 (en) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
WO2007015167A2 (en) * 2005-08-02 2007-02-08 Novartis Vaccines And Diagnostics Srl Reducing interference between oil-containing adjuvants and surfactant-containing antigens
EP1951296B2 (en) 2005-11-01 2014-07-23 Novartis Vaccines and Diagnostics GmbH Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DK1951299T3 (da) 2005-11-04 2012-04-02 Novartis Vaccines & Diagnostic Influenzavacciner indeholdende kombinationer af partikelformige adjuvanser og immunforstærkere
EP1951301A2 (en) * 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
US20090304742A1 (en) * 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
EP3714900A1 (en) 2005-11-04 2020-09-30 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP6087041B2 (ja) 2006-01-27 2017-03-08 ノバルティス アーゲー 血球凝集素およびマトリックスタンパク質を含むインフルエンザウイルスワクチン
EP2004226A1 (en) * 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
PL2054431T3 (pl) 2006-06-09 2012-07-31 Novartis Ag Konformery adhezyn bakteryjnych
DK2043682T3 (da) 2006-07-17 2014-06-02 Glaxosmithkline Biolog Sa Influenzavaccine
EA200900024A1 (ru) 2006-07-17 2009-06-30 Глаксосмитклайн Байолоджикалс С.А. Противогриппозная вакцина
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP3456348A1 (en) 2006-09-11 2019-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8084443B2 (en) 2007-10-01 2011-12-27 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
ES2393162T3 (es) 2007-06-27 2012-12-19 Novartis Ag Vacunas antigripales con un contenido reducido de aditivos
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US8821885B2 (en) 2007-08-27 2014-09-02 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
AU2008293513B2 (en) * 2007-08-28 2013-11-21 Nanotherapeutics, Inc. Method for producing viral vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081172A1 (en) * 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
EA201001479A1 (ru) 2008-04-16 2011-06-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
CA2741961A1 (en) 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
JP2012517416A (ja) 2009-02-10 2012-08-02 ノバルティス アーゲー 増加した量のｈ３抗原を含むインフルエンザワクチン
ES2552383T3 (es) 2009-02-10 2015-11-27 Novartis Ag Regímenes de vacuna de la gripe para cepas asociadas a pandemias
ES2608841T3 (es) 2009-02-10 2017-04-17 Seqirus UK Limited Vacunas contra la gripe con cantidades reducidas de escualeno
EP2424565A1 (en) 2009-04-27 2012-03-07 Novartis AG Adjuvanted vaccines for protecting against influenza
AU2010250832B2 (en) 2009-05-21 2013-10-03 Seqirus UK Limited Reverse genetics using non-endogenous pol I promoters
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9821052B2 (en) 2009-07-31 2017-11-21 Seqirus UK Limited Reverse genetics systems
JP2013504556A (ja) 2009-09-10 2013-02-07 ノバルティス アーゲー 気道疾患に対する組み合わせワクチン
WO2011048560A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
AU2010325748B2 (en) 2009-12-03 2014-04-17 Seqirus UK Limited Hydrophilic filtration during manufacture of vaccine adjuvants
CN102740832B (zh) 2009-12-03 2016-01-13 诺华股份有限公司 就微流化排列交互作用和背压室
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
WO2011067673A2 (en) 2009-12-03 2011-06-09 Novartis Ag Circulation of components during homogenization of emulsions
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EA201290897A1 (ru) 2010-03-11 2013-03-29 Иммьюн Дизайн Корп. Вакцины для пандемического гриппа
KR20130079398A (ko) 2010-05-06 2013-07-10 노파르티스 아게 미생물 불활성화를 위한 유기 과산화 화합물
CN105125488A (zh) 2010-05-12 2015-12-09 诺华股份有限公司 制备鲨烯的改良方法
JP5876036B2 (ja) 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
KR20130081659A (ko) 2010-06-01 2013-07-17 노파르티스 아게 인플루엔자 백신 항원의 농축 및 동결건조
KR102113512B1 (ko) 2010-06-01 2020-05-22 노파르티스 아게 동결건조하지 않는 인플루엔자 백신 항원의 농축
WO2011154976A2 (en) 2010-06-08 2011-12-15 Panacea Biotec Limited Improved influenza vaccine
EP2590674B1 (en) 2010-07-06 2017-02-22 Variation Biotechnologies Inc. Compositions and methods for treating influenza
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
EP3012330A1 (en) 2010-09-07 2016-04-27 Novartis AG Generic assays for detection of mammalian reovirus
WO2012055951A2 (en) 2010-10-27 2012-05-03 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP2663288B1 (en) 2011-01-13 2022-12-21 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
JP5798356B2 (ja) * 2011-04-06 2015-10-21 一般財団法人化学及血清療法研究所 新規インフルエンザワクチン安定化剤
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
AU2012324398A1 (en) 2011-10-20 2014-05-01 Seqirus UK Limited Adjuvanted influenza B virus vaccines for pediatric priming
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
EP3494989A1 (en) 2012-01-26 2019-06-12 Longhorn Vaccines and Diagnostics, LLC Composite antigenic sequences and vaccines
AU2013213345A1 (en) 2012-01-27 2014-08-28 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
CN103608453B (zh) 2012-03-02 2018-07-24 思齐乐 流感病毒重配
GB201205189D0 (en) 2012-03-23 2012-05-09 Glaxosmithkline Biolog Sa Novel medical use
US20130315955A1 (en) * 2012-04-13 2013-11-28 Protein Sciences Corporation Stability and potency of hemagglutinin
US20150161359A1 (en) 2012-06-04 2015-06-11 Novartis Ag Methods for safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
AU2013354219A1 (en) 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren
CA2897752A1 (en) 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
CA2905612A1 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
AU2014264501A1 (en) 2013-05-10 2015-12-10 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
AU2014276418A1 (en) 2013-06-06 2016-01-21 Novartis Ag Influenza virus reassortment
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
WO2015079952A1 (ja) 2013-11-29 2015-06-04 テルモ株式会社 アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法
ES2861806T3 (es) 2014-12-02 2021-10-06 Novartis Ag Fabricación de composiciones que contienen tensioactivo
EP3294448A4 (en) 2015-05-14 2018-12-12 Longhorn Vaccines and Diagnostics, LLC Rapid methods for the extraction of nucleic acids from biological samples
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
WO2017167768A1 (en) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Novel vaccine composition
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CN113993542A (zh) 2019-01-30 2022-01-28 葛兰素史密丝克莱恩生物有限公司 用于自乳化的油/表面活性剂混合物
BR112022009545A2 (pt) 2019-11-18 2022-10-11 Seqirus Pty Ltd Método para produzir vírus influenza recombinantes
RU2754398C1 (ru) * 2020-06-25 2021-09-01 Общество с ограниченной ответственностью «ФОРТ» Способ получения четырехвалентной вакцины для профилактики гриппа
AU2021302954A1 (en) 2020-06-30 2023-02-16 Seqirus UK Limited Cold filtration of oil-in-water emulsion adjuvants
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US639A (en) 1838-03-17 of boston
US5520A (en) 1848-04-18 Oegan-pipb
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
NO902352L (no) * 1989-05-29 1990-11-30 Lion Corp Fremgangsmaate for fremstilling av en vaksine mot dental karies, samt vaksineblandinger for anvendelse som nesedraaper
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
HU219808B (hu) 1992-06-25 2001-08-28 Smithkline Beecham Biologicals S.A. Adjuvánst tartalmazó vakcinakompozíció és eljárás annak előállítására
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
EP0750907B1 (en) * 1995-06-30 2002-03-20 American Cyanamid Company Stable macrolide and macrolide vaccine compositions
US20020165168A1 (en) * 1995-12-16 2002-11-07 Joachim Bunger Use of sugar derivatives as antimicrobial, antimycotic and/or antiviral active substances
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
DE19649895A1 (de) * 1996-12-02 1998-06-04 Henkel Kgaa Schäumende Körperreinigungsmittel
AU5910998A (en) * 1997-01-13 1998-08-03 Emory University Compounds and their combinations for the treatment of influenza infection
GB9705740D0 (en) * 1997-03-20 1997-05-07 Medeva Europ Ltd A method of preservation
BR9811262A (pt) 1997-04-01 2000-10-17 Ribi Immunochem Research Inc Composições auxiliares imunológicas aquosas de lipìdio de monofosforila a.
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
DE69838992T2 (de) * 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
FR2780278B1 (fr) * 1998-06-24 2001-01-19 Oreal Composition conditionnante et detergente et utilisation
DE19841796A1 (de) 1998-09-12 2000-03-16 Beiersdorf Ag Kombinationen von Antiadhäsiva (Kohlenhydrate) und Mikrobiziden
PL203951B1 (pl) * 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
AUPQ233799A0 (en) * 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
WO2001021152A1 (en) * 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
ATE376825T1 (de) * 1999-09-24 2007-11-15 Glaxosmithkline Biolog Sa Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
BR0014282A (pt) * 1999-09-24 2002-05-21 Smithkline Beecham Biolog Vacinas
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
RU2228177C2 (ru) 1999-10-19 2004-05-10 Дзе Проктер Энд Гэмбл Компани Назальная композиция и способ профилактики и лечения простуды и гриппа вирусного происхождения
IL155073A0 (en) * 2000-10-02 2003-10-31 Glaxosmithkline Biolog Sa Split enveloped virus preparation
WO2002067983A1 (en) * 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US9856414B2 (en) 2013-06-10 2018-01-02 Dober Chemical Corp. Compositions, systems and methods of making coated additive components

Also Published As

Publication number Publication date
NZ529755A (en) 2005-11-25
CZ298697B6 (cs) 2007-12-27
TWI228420B (en) 2005-03-01
DE60230760D1 (de) 2009-02-26
CN101069744A (zh) 2007-11-14
BRPI0210076A8 (pt) 2017-05-23
HU229368B1 (en) 2013-11-28
IL188834A (en) 2011-01-31
AU2002344182B2 (en) 2006-01-05
US7316813B2 (en) 2008-01-08
AU2006200742A1 (en) 2006-03-16
US20080181914A1 (en) 2008-07-31
BRPI0210076B1 (pt) 2020-01-07
CA2448208A1 (en) 2002-12-05
NO335212B1 (no) 2014-10-20
EP2039761A1 (en) 2009-03-25
CN1533434A (zh) 2004-09-29
PL366990A1 (en) 2005-02-07
CN1279165C (zh) 2006-10-11
JP2004527264A (ja) 2004-09-09
AU2006200742C1 (en) 2014-10-16
WO2002097072A8 (en) 2004-02-19
AR036039A1 (es) 2004-08-04
AU2002344182C1 (en) 2014-11-06
CA2448208C (en) 2011-11-29
SI1407008T1 (sl) 2009-06-30
HUP0400445A3 (en) 2011-06-28
PL206435B1 (pl) 2010-08-31
DK1407008T3 (da) 2009-04-27
WO2002097072A2 (en) 2002-12-05
HUP0400445A2 (hu) 2004-07-28
CN101069744B (zh) 2012-04-25
WO2002097072A3 (en) 2003-04-24
EP1407008A2 (en) 2004-04-14
CY1108930T1 (el) 2014-07-02
ATE420159T1 (de) 2009-01-15
MXPA03010944A (es) 2005-04-08
CZ20033253A3 (cs) 2004-04-14
EP1407008B1 (en) 2009-01-07
FR13C0072I1 (fr) 2014-01-31
KR20040025682A (ko) 2004-03-24
EP2495314A1 (en) 2012-09-05
CO5540349A2 (es) 2005-07-29
HK1067891A1 (en) 2005-04-22
AU2006200742B2 (en) 2010-05-27
MY134424A (en) 2007-12-31
US20040241187A1 (en) 2004-12-02
ES2318020T3 (es) 2009-05-01
IL188834A0 (en) 2009-02-11
PT1407008E (pt) 2009-02-26
ZA200309250B (en) 2005-05-25
IL158931A (en) 2008-04-13
BR0210076A (pt) 2004-06-22
AU2006200742C9 (en) 2015-03-26
JP4074582B2 (ja) 2008-04-09
NO20035208D0 (no) 2003-11-24
KR100871021B1 (ko) 2008-11-27

Similar Documents

Publication Publication Date Title
BRPI0210076B8 (pt) preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato
ES2357752T3 (es) Reducción de riesgos latrogénicos potenciales asocidos con vacunas.
BR112022024248A2 (pt) Vacinas de combinação à base de ácido nucleico
BR9911163A (pt) Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo
JP2004527264A5 (pt)
BR0014281A (pt) Vacina contra vìrus de gripe intranasal
BR0113822A (pt) Vacina
BRPI0208183B8 (pt) peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
ES2553113T3 (es) Vacuna
BR0208301A (pt) Vacinas de ácido nucléico para prevenção de infecção por flavivìrus
ES2552383T3 (es) Regímenes de vacuna de la gripe para cepas asociadas a pandemias
BR0205684A (pt) Compostos cìclicos fundidos e seu uso medicinal
BR0114393A (pt) Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado
BR0312474A (pt) Partìcula viral adjuvante
NZ592713A (en) Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
BR0104895A (pt) Disco provido de pás
NO985821L (no) Substituerte syklopentanforbindelser som er nyttige som neuraminidaseinhibitorer
ME00491B (me) Vakcina protiv bolesti zapadnog nila
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR9814204A (pt) "obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral"
BR112022017923A2 (pt) Tratamento de infecção por coronavírus
BR0112497A (pt) Antìgenos de streptococcus pyogenes
BR0009476A (pt) Esteróides imunomoduladores, em particular hemidrato de 16 alfa-bromoepiandrosterona
TW200617166A (en) Multivalent avian influenza vaccines
BRPI0417680A (pt) plasma sangüìneo inativado de vìrus universalmente aplicável produzido a partir das porções de plasma não-caucasiano

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 7/04

Ipc: C12N 7/04 (2006.01), A61K 39/145 (2006.01), A61P 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: GLAXOSMITHKLINE BIOLOGICALS BRANCH OF SMITHKLINE B

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29/05/2022